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Estrogen’s role in cell growth and proliferation has long been appreciated both
in the normal development of secondary sexual characteristics and in diseased
states in cancers of the breast, ovaries and uterus. We are beginning to appre-
ciate estrogen’s expanded role in maintaining such diverse functions as the
skin’s elasticity, the health of the central nervous system, bone density and
cardiac health. Estrogen plays out its roles in varied tissues by binding to
two major ligand activated nuclear receptors, estrogen receptor alpha (ER-a)
and estrogen receptor beta (ER-b). The interrelationship of the two receptors
plays a role in the responsiveness of certain breast cancers to drug treatment.
Though the ligand binding sites of the two receptors differ by only two amino
acids, the overall degree of homology between ER-a and ER-b is low. The
body uses the receptor selectivity to its advantage by dispersing the receptors
in varying ratios to different tissues. Of these actions ER-a is thought to be re-
sponsible for the majority with ER-b playing a minor role in all and having
more significance in the cardiovascular and skeletal systems. Small molecules
have been identified which bind to one or the other receptors with differing
binding affinities. These selective estrogen receptor modulators (SERMs) hold
the potential to be pharmacologically effective in treating diseases specific
to one type of estrogen receptor while not affecting the other. For example,
ER-a and ER-b are both present in breast tissue, and the ratio of beta to alpha
is being examined as one indicator in determining the likelihood of successful
treatment of breast cancer by certain drugs. Here we use changes in the fluo-
rescence polarization to calculate binding affinities for each of several small
molecules to ER-a and ER-b.
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The NMDA family of ionotropic glutamate receptors are ligand-gated ion
channels that mediate the majority excitatory synaptic transmission in the
brain. Dysfunction of NMDA receptor signalling is involved in a range of neu-
rological and psychiatric diseases for which NMDA receptors are considered
important drug targets. NMDA receptors are tetrameric assemblies comprised
of two glycine-binding GluN1 subunits and two glutamate-binding GluN2 sub-
units. Four different GluN2 subunits (GluN2A-D) exist with distinct expression
and functional profiles. Identification of subunit-selective NMDA receptor ag-
onists, antagonists, or modulators could prove to be both valuable pharmaco-
logical tools as well as potential new therapeutic agents.
Polyamine toxins are a group of small molecules found in spiders and wasps
that are open-channel blockers of NMDA receptors. Polyamine toxins have
found valuable use as pharmacological tools based on their high affinity and
selectivity, but have not yet been explored as templates for the development
of NMDA receptor drugs. Argiotoxin-636 (ArgTX-636) is a polyamine toxin
isolated from the venom of the orb weaver spider Argiope lobata. ArgTX-
636 is among the most potent inhibitors of NMDA receptors and blocks these
in a use- and voltage-dependent manner, presumably by binding to the ion
channel region. We have recently shown that modifications within the poly-
amine tail of ArgTX-636 can control subtype selectivity. In this study, we
explore the rational design of ArgTX-636 analogs to produce NMDA receptor
inhibitors with marked improvement in subtype selectivity. Systematic varia-
tion of the polyamine tail lead to identification of ArgTX analogs with pro-
nounced subtype selectivity, such as 100-fold differential potency between
GluN2A, GluN2B, or GluN2C versus GluN2D containing receptors. To study
the structural basis for NMDA subtype selectivity, compounds were docked
into models of the NMDA receptor ion channels.
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EmrE and SugE are members of the small multidrug resistance protein family
that can efflux quaternary cation compounds (QCC) via proton motive force
within the Escherichia coli plasma membrane. Members of this integral mem-
brane protein family are characterized by their short (~100-140 amino acids)
four transmembrane (TM) alpha- helix conformation and highly conservedglutamate residue within the active site. EmrE protein can confer broad mul-
tidrug resistance to the host strain unlike SugE protein, which demonstrates
limited multidrug resistance. The exact multimeric state or states of both pro-
teins during transport and ligand binding is not well understood and often
yield conflicting results that are specific to the conditions of study. To explore
SMR multimerization as influenced by QCC ligands, organic solvent extracted
EmrE and SugE protein from E. coli membranes were characterized in the de-
tergents, sodium dodecyl sulfate (SDS) and dodecyl maltoside (DDM) at
varying protein concentrations. SMR proteins solubilized in both detergents
demonstrated a predominately monomeric state but upon increasing particular
QCC ligand concentrations resulted in multimer formation or enhancement
using SDS- tricine polyacrylamide gel electrophoresis (PAGE). The results
from this PAGE based assay demonstrate that: i) SMR multimers are induced
by particular ligands that may relate to ligand shape and ii) only EmrE multi-
merization is induced by particular ligands, whereas SugE appears to be
insensitive to drug enhanced oligomerization. Therefore, SMR multimer
variability may be dependent upon the nature of the transported substrate
and SMR subclass; only EmrE can alter its subunit composition in response
to particular QCC substrates. This PAGE based assay provides the framework
to explore the influence of diverse QCC substrates for its affects on SMR
multimerization.
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CLC chloride channels and transporters play diverse physiological roles.
Small-molecule inhibitors of the CLCs would be powerful tools to understand
and potentially treat a variety of CLC-related human diseases. In addition to
their potential therapeutic benefits, inhibitors can be used to trap channels or
transporters in particular conformational states, potentially advancing our un-
derstanding of the structural basis for CLC activity. Despite their usefulness,
specific small molecule inhibitors for CLC proteins are scarce. To address
this shortfall, we have embarked on a search for novel inhibitors of the CLC
proteins. We have discovered a panel of small molecules active against both
the human ClC-K and the prokaryotic ClC-ec1 homologs. Because ClC-ec1
is amenable to structural studies by X-ray crystallography, co-crystallization
experiments with these novel inhibitors are in progress. As an alternative
method to identifying the inhibitor-binding site, we have synthesized photo-re-
active diazirine derivatives of the inhibitors and shown that these photo-affinity
reagents specifically inhibit ClC-ec1. Experiments to identify the binding site
using protease digestion coupled with mass spectrometry are currently under-
way. Once located, protein/inhibitor interactions gleaned from the labeling of
ClC-ec1 could allow us to rationally design more potent inhibitors of mamma-
lian transporters and channels.
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The widespread use of antibody therapeutics and the emergence of proteases as
compelling disease targets contrast sharply with our poor understanding of how
antibodies achieve protease inhibition. Recent structural studies have outlined
the mechanism of serine protease inhibition by active site-directed antibodies.
However, the molecular basis of allosteric inhibition by antibodies has been
elusive. The present study, with three crystal structures and a comprehensive
kinetic analysis, now provides a detailed view of how an allosteric antibody in-
hibits protease activity. We determined the structure (2.35 A˚ resolution) of the
trypsin-like serine protease hepatocyte growth factor activator (HGFA) in com-
plex with the allosteric antibody Ab40, a competitive inhibitor of HGFA cata-
lytic activity. The antibody binds at the periphery of the substrate binding cleft
and imposes a conformational change on the entire 99-loop (chymotrypsinogen
numbering). Remarkably, a single residue deletion (Trp96H) of Ab40 abol-
ished inhibition of HGFA activity commensurate with the reversal of the
99-loop conformation to its ‘competent’ state as evidenced from the structure
of HGFA/ Fab40.DTrp96H resolved at 2.9 A˚. In order to understand the precise
mechanism by which Ab40 interferes with the proteolytic activity of HGFA, we
determined the structure of HGFA/Fab40.DTrp96H in complex with substrate-
mimicking peptidic inhibitor (Ac-KQLR-chloromethlyketone) at 2.7 A˚. Com-
parison of these three structures led us to propose a model wherein the binding
of Ab40 to HGFA and the concomitant change in the conformation of the
99-loop may result in the partial collapse of substrate binding subsite S2 and
the reorganization of subsite S4, leading to the inhibition of HGFA activity
